Inactive Instrument

Highlights Tokai Pharmaceuticals Inc Nasdaq

Equities

US88907J1079

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

Eledon Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 28	CI
Eledon Pharmaceuticals Says 12th Participant Enrolled in Tegoprubart Trial; Shares Rise After Hours	Mar. 25	MT
Eledon Pharmaceuticals Announces 12th Participant Enrolled in Phase 2 BESTOW Trial Evaluating Tegoprubart for the Prevention of Organ Rejection	Mar. 25	CI
Sector Update: Health Care Stocks Higher in Late Afternoon Trading	Mar. 21	MT
Sector Update: Health Care	Mar. 21	MT
Eledon Pharmaceuticals Says Tegoprubart Used in Kidney Transplant From Pig to Human	Mar. 21	MT
Eledon Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 09	CI
Eledon Pharmaceuticals, Inc. Reports Updated Data from Ongoing Phase 1B Trial Evaluating Tegoprubart for Prevention of Rejection in Kidney Transplantation	Nov. 02	CI
Eledon Pharmaceuticals, Inc. Announces Publication of Study Evaluating Tegoprubart as an Immunomodulatory Monotherapy in Nonhuman Primate Kidney and Islet Allotransplants	23-09-06	CI
Eledon Pharmaceuticals, Inc. Announces First Participant Dosed in Phase 2 Bestow Trial Evaluating Tegoprubart for the Prevention of Rejection in Kidney Transplantation	23-09-05	CI
Eledon Pharmaceuticals, Inc. Announces Dosing of 10th Patient in Ongoing Phase 1b Trial Evaluating Tegoprubart in Patients Undergoing Kidney Transplantation	23-08-16	CI
Eledon Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-10	CI
Eledon Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-11	CI
Eledon Pharmaceuticals, Inc. Reports Data from Ongoing Phase 1B Trial Evaluating Tegoprubart in Patients Undergoing Kidney Transplantation At World Congress of Nephrology	23-03-31	CI
Eledon Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-30	CI
Egenesis and Eledon Pharmaceuticals Announces Collaboration for Use of Tegoprubart in Preclinical Xenotransplantation Studies	23-01-09	CI
Eledon Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-14	CI
Eledon Pharmaceuticals, Inc. Receives FDA Clearance of IND Application to Evaluate Tegoprubart in IgA Nephropathy	22-09-06	CI
Eledon Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-11	CI
Eledon Pharmaceuticals Receives FDA Clearance of IND Application to Evaluate Tegoprubart for the Prevention of Rejection in Kidney Transplant Recipients	22-08-01	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Tokai Pharmaceuticals Inc Nasdaq

Equities

US88907J1079

Highlights

Filters